Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17241940 | 0.87 | HDAC1 (0.59) | MAPK1HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL17242660 | 0.80 | MAPT (0.66) | MAPK1HDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL12963428 | 0.79 | PGR (0.61) | THRBTP53PGR | |
| SCHEMBL30485670 | 0.79 | PGR (0.68) | MAPK1HDAC1MDM2TP53PGR | |
| SCHEMBL6362477 | 0.79 | PGR (0.68) | MAPK1HDAC1MDM2TP53PGR | |
| SCHEMBL24031061 | 0.78 | HDAC1 (1.00) | HDAC1HDAC11HDAC8HDAC6RXFP1 | |
| SCHEMBL16092736 | 0.77 | MEN1 (0.65) | THRBTP53PGR | |
| SCHEMBL17242731 | 0.77 | MAPT (0.63) | HDAC1HDAC11HDAC8HDAC6TP53 | |
| SCHEMBL6366020 | 0.73 | PGR (0.64) | MAPK1PGR | |
| SCHEMBL8347752 | 0.71 | MAPK8 (0.55) | HDAC1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | ORION CORPORATION (FI) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137387-A1 | PHARMACOLOGICALLY ACTIVE QUINAZOLINEDIONE DERIVATIVES | GABRB1, GABRB3, GABRB2 | MAPK1 3124/4885HDAC1 1565/4885HDAC11 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.